A detailed history of Advisor Group Holdings, Inc. transactions in Xencor Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 35 shares of XNCR stock, worth $866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35
Previous 35 -0.0%
Holding current value
$866
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$18.21 - $24.5 $3,368 - $4,532
-185 Reduced 84.09%
35 $0
Q1 2024

May 10, 2024

SELL
$18.65 - $26.52 $5,147 - $7,319
-276 Reduced 55.65%
220 $4,000
Q4 2023

Feb 12, 2024

SELL
$16.53 - $21.42 $2,810 - $3,641
-170 Reduced 25.53%
496 $10,000
Q3 2023

Nov 13, 2023

BUY
$20.08 - $25.39 $2,048 - $2,589
102 Added 18.09%
666 $13,000
Q2 2023

Aug 10, 2023

BUY
$24.77 - $29.9 $272 - $328
11 Added 1.99%
564 $14,000
Q1 2023

May 12, 2023

SELL
$25.95 - $36.95 $5,657 - $8,055
-218 Reduced 28.27%
553 $15,000
Q4 2022

Feb 10, 2023

BUY
$24.79 - $30.86 $1,660 - $2,067
67 Added 9.52%
771 $20,000
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $5,711 - $7,526
232 Added 49.15%
704 $18,000
Q2 2022

Aug 10, 2022

SELL
$19.74 - $29.01 $2,428 - $3,568
-123 Reduced 20.67%
472 $13,000
Q1 2022

May 04, 2022

BUY
$26.68 - $41.63 $1,280 - $1,998
48 Added 8.78%
595 $16,000
Q3 2021

Nov 05, 2021

SELL
$30.65 - $35.68 $122 - $142
-4 Reduced 0.73%
547 $18,000
Q2 2021

Aug 02, 2021

BUY
$34.33 - $44.68 $6,145 - $7,997
179 Added 48.12%
551 $19,000
Q1 2021

May 13, 2021

BUY
$40.81 - $53.88 $571 - $754
14 Added 3.91%
372 $17,000
Q3 2020

Nov 12, 2020

BUY
$30.09 - $43.02 $1,895 - $2,710
63 Added 21.36%
358 $13,000
Q2 2020

Aug 14, 2020

SELL
$27.76 - $33.42 $120,839 - $145,477
-4,353 Reduced 93.65%
295 $10,000
Q1 2020

May 18, 2020

BUY
$20.69 - $37.79 $96,167 - $175,647
4,648 New
4,648 $139,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.48B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.